FDA
-
-
-
-
-
-
-
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
-
-
-
-
-
-
-
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Atea Pharmaceuticals Inc. (AVIR) Granted FDA Fast Track Designation for Bemnifosbuvir
-
-
-
-
-
-
-
Atea Pharmaceuticals Inc. (AVIR) to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19
-
-
-
-
-
-
-
CAS Group Announces Glass Lewis Recommendation That Aviragen Stockholders Vote AGAINST Merger and Emphasizes Value of Teslexivir (BTA074) Program
-
-
-
-
-
-
-
Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

